Generation Bio Appoints Ron Cooper to Its Board of Directors
February 18 2021 - 7:30AM
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines
company creating a new class of gene therapy, announced today that
Ron Cooper has been appointed to its Board of Directors. The
appointment is effective March 1, 2021.
Ron Cooper is a global biopharmaceutical executive who currently
serves as president, chief executive officer and board member of
Albireo Pharma, Inc., a position he has held since June 2015. He
has successfully matured Albireo Pharma, Inc. to a clinical-stage
public company on the verge of its first drug approval. Prior to
joining Albireo Pharma, Inc., Cooper had a 25-year career at
Bristol Myers Squibb, during which time he held multiple leadership
roles in sales, marketing and general management, culminating in
his role as president of Europe.
“We are excited to welcome Ron to our Board of Directors during
this critical stage of Generation Bio’s evolution,” said Geoff
McDonough, M.D., president and chief executive officer of
Generation Bio. “Ron is a highly seasoned and respected life
sciences executive, and we look forward to his expertise,
engagement and assistance as we advance our work toward the clinic.
His global commercial experience and current work in rare diseases
will be a great addition to our Board and organization as a
whole.”
“First generation gene therapy has both great promise and
limitations. Generation Bio’s unique non-viral platform has the
potential to significantly expand the reach of gene therapy through
redosing and scale,” Cooper stated. “I look forward to joining the
Board of this dynamic and growing company that could have a
positive impact on patients.”
About Generation Bio
Generation Bio is an innovative genetic medicines company
focused on creating a new class of non-viral gene therapy to
provide durable, redosable treatments for people living with rare
and prevalent diseases. The company’s non-viral platform
incorporates a proprietary, high-capacity DNA construct called
closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle
delivery system, or ctLNP; and an established, scalable capsid-free
manufacturing process. The platform is designed to enable
multi-year durability from a single dose of ceDNA and to allow
titration and redosing if needed. The ctLNP is designed to deliver
large genetic payloads, including multiple genes, to specific
tissues to address a wide range of indications. The company’s
efficient, scalable manufacturing process supports Generation Bio’s
mission to extend the reach of gene therapy to more people, living
with more diseases, in more places around the world.
For more information, please visit www.generationbio.com.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about our
strategic plans or objectives, our technology platforms, our
research and clinical development plans, and other statements
containing the words “believes,” “anticipates,” “plans,” “expects,”
and similar expressions, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act
of 1995. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important
factors, including: uncertainties inherent in the identification
and development of product candidates, including the conduct of
research activities, the initiation and completion of preclinical
studies and clinical trials and clinical development of the
Company’s product candidates; whether results from preclinical
studies will be predictive of the results of later preclinical
studies and clinical trials; expectations for regulatory approvals
to conduct trials or to market products; challenges in the
manufacture of genetic medicine products; the Company’s ability to
obtain sufficient cash resources to fund the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements; and the impact of the COVID-19 pandemic on the
Company’s business and operations; as well as the other risks and
uncertainties set forth in the “Risk Factors” section of our most
recent quarterly report on Form 10-Q, which is on file with the
Securities and Exchange Commission, and in subsequent filings the
Company may make with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent the Company’s views as of the date hereof. The
Company anticipates that subsequent events and developments will
cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in
the future, the Company specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date on which they were made.
Contacts:
InvestorsMaren KillackeyGeneration
Bio541-646-2420mkillackey@generationbio.com
MediaAlicia WebbGeneration
Bio847-254-4275awebb@generationbio.com
Stephanie SimonTen Bridge
Communications617-581-9333stephanie@tenbridgecommunications.com
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024